← All trials
NCT05016349
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2021
- Primary completion
- Oct 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Aug 23, 2021
- Last posted
- Aug 23, 2021
- Enrollment
- 160
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of Saudi ArabiaLead sponsor
- Kafrelsheikh UniversitySponsor investigator
- Government of Saudi ArabiaCollaborator
- Damitta UniversityOverall official - principal investigator
- Government of Saudi ArabiaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.